Redefining Treatment Approaches in Advanced Triple-Negative Breast Cancer

Panelist discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer.

EP. 1: Current Frontline Treatment Approaches and Challenges in Advanced TNBC

October 30th 2025

Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer

EP. 2: Contextualizing Data for Frontline Sacituzumab Govitecan Plus Pembrolizumab in PD-L1+ TNBC

October 30th 2025

Panelists break down data from the ASCENT-04 trial evaluating sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer.

EP. 3: ASCENT-03: Data for Frontline Sacituzumab Govitecan in IO-Ineligible TNBC

November 5th 2025

Panelists highlight findings from the ASCENT-03 trial evaluating sacituzumab govitecan in triple-negative breast cancer ineligible for immunotherapy.

EP. 4: Safety Profile of Sacituzumab Govitecan–Based Treatment in Frontline TNBC

November 5th 2025

Panelists discuss safety considerations for sacituzumab govitecan–based therapy in frontline triple-negative breast cancer.

EP. 5: Addressing Sequencing Questions With TROP-2–Directed ADCs in TNBC

November 12th 2025

Panelists discuss sequencing considerations as more TROP-2–directed antibody-drug conjugates are evaluated in triple-negative breast cancer.

EP. 6: Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC

November 12th 2025

Panelists discuss findings from the TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan in immunotherapy-ineligible triple-negative breast cancer.

EP. 7: Highlighting Additional Key TNBC Data From ESMO 2025

November 19th 2025

Panelists break down other key triple-negative breast cancer data presented at the 2025 ESMO Congress.

EP. 8: Ongoing Research to Watch in TNBC

November 19th 2025

Panelists spotlight key trials and drugs to watch in ongoing research in triple-negative breast cancer.